Evidence Hub

Pharmacological Management of Diabetic Neuropathy: Current Evidence, Clinical Positioning, and Emerging Therapeutic Targets

Alburghaif AH, Al-Hussaniy HA, Maan J, Razzaq NA

Current neuropharmacology, 2026

Abstract

BACKGROUND: Diabetic neuropathy is one of the most serious complications of diabetes mellitus, which is associated with pain, loss of sensation, and numbness in the extremities. Several cellular triggers, such as oxidative stress, inflammation, and glycation products, all cause nerve damage. These changes affect quality of life and may cause ulcers or amputations, so effective management is essential.

OBJECTIVES: This review is conducted to identify and summarize the main pharmacological strategies that are used in the treatment of diabetic neuropathy, both the approved treatments and those that are currently under research.

METHODS: This review was conducted by searching scientific databases and repositories, including Google Scholar, PubMed, and DOAJ, using keywords such as diabetic neuropathy, pharmacological treatment of pain, and antidepressant. After excluding articles, the final number of articles included in our study was approximately 107, comprising clinical studies and review articles.

RESULTS: Tricyclic antidepressants as well as serotonin-norepinephrine reuptake inhibitors have been proven to help with neuropathic pain but can be associated with sedation or gastrointestinal side effects. The anticonvulsants, including pregabalin and gabapentin, decrease neuronal excitability and are reliable in reducing pain. Local therapies, such as capsaicin and lidocaine, are more local and less systemic. Opioids are also used in the treatment of recalcitrant cases due to…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free